6LJ.MU Stock Analysis
6L
Uncovered
Matinas BioPharma Holdings Inc is uncovered by Eyestock quantitative analysis.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Low score
Matinas BioPharma Holdings, Inc. is a clinical-stage biopharmaceutical company, which focuses on enabling the delivery of life-changing medicines using its LNC platform technology. The company is headquartered in Bedminster, New Jersey and currently employs 31 full-time employees. The company went IPO on 2014-06-03. The firm is focused on redefining the intracellular delivery of nucleic acids and small molecules through its lipid nanocrystal (LNC) drug delivery platform. The firm is engaged in developing LYPDISO, as well as its LNC platform delivery technology and a pipeline of associated product candidates, including MAT2203 and MAT2501. Its LNC platform is designed to deliver a range of medicines, including small molecules, drugs with blood level-limiting toxicities, nucleic acid polymers, proteins, peptides, vaccines, and gene editing technologies. LYPDISO is a prescription-only omega-3 fatty acid-based composition, comprised primarily of eicosapentanoic acid (EPA) and docosapentanoic acid (DPA), intended for the treatment of cardiovascular and metabolic conditions. MAT2203 is an oral and non-toxic encochleated form of amphotericin B (CAmB). MAT2501 is an LNC formulation of the gram-negative antibiotic agent amikacin.